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Introduction {#sec001}
============

Inhalation of H~2~ is reported to have beneficial effects in living organisms \[[@pone.0234626.ref001], [@pone.0234626.ref002]\], and clinical trials have demonstrated its efficacy and safety in patients with acute myocardial infarction \[[@pone.0234626.ref003]\] and post-resuscitation cardiac arrest \[[@pone.0234626.ref004], [@pone.0234626.ref005]\]. On March 3, 2020, the Chinese National Health and Medical Commission recommended "conditional treatment with hydrogen and oxygen inhalation" in addition to the general oxygen therapy measures in the treatment section of the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7), in accordance with a recommendation notification by the Chinese Non-government Medical Institutions Association \[[@pone.0234626.ref006]\]. However, the kinetics of inhaled H~2~ in the body have not been sufficiently analyzed to date.

We previously measured, in rats, the time course of H~2~ levels in different tissues after continuous H~2~ inhalation, by inserting a needle-type sensor electrode directly into the tissues \[[@pone.0234626.ref007], [@pone.0234626.ref008]\]. However, since the response of the needle-type hydrogen sensor electrode is slow, this makes it unsuitable for measuring short-term changes in H~2~ concentration in tissues.

In a non-clinical pharmacokinetic study, the distribution of a test drug to various organs and tissues after a single or repeated dose and its change over time should be investigated. In the case of gas, unlike oral and injectable drugs, a non-clinical pharmacokinetic study with a single dose has not been performed. This was because there was no animal protocol for a single-dose study of the gas. The same is true for H~2~. It remained undetermine whether H~2~ diffused from the lungs in a blood flow-independent manner or whether H~2~ was transported throughout the body in a blood flow-dependent manner. Therefore, in the present study, we devised an animal protocol for single-dose inhalation of gas and proved the latter to be true for the first time.

The most effective way of taking H~2~ into circulating blood after a single inhalation is by fully exhaling, then inhaling 100% H~2~ to the maximum inspiration position, and holding your breath for as long as you can endure. In the present study, we examine the pharmacokinetics of H~2~ by replicating this single inhalation method in pigs.

Materials and methods {#sec002}
=====================

Animals {#sec003}
-------

The present study was designed according to the principles of the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines \[[@pone.0234626.ref009]\]. Experiments were performed in accordance with the institutional guidelines and the Japanese law on the protection and management of animals. The full ethical proposal was approved by the Research Council and Animal Care and Use Committee of Keio University \[approval no: 12094-(7)\].

Two female pigs, weighing 22.4 kg and 22.0 kg, were housed in separate cages under temperature- and light-controlled conditions (12-h light/dark cycle) and provided with food and water ad libitum. The pigs were fasted for 12 h prior to surgery, with free access to water. Sedation with medetomidine (0.02 mg/kg) and midazolam (0.1 mg/kg) was followed by endotracheal intubation and mechanical ventilation. Anesthesia was maintained with inhalational isoflurane. Surgery was performed by a surgeon with experience of more than 200 clinical transplant operations, who is a steering member of the transplantation society and a permanent director of the transplantation society of Japan (E.K.).

Catheter insertion {#sec004}
------------------

Before insertion, a catheter (Argyle Medecut LCV-UK kit, 16 GX, 70 cm) was filled with heparinized saline, and the blood collection site was equipped with a three-way stopcock (TERUMO terfusion three-way stopcock, R type). Once at a sufficient depth of anesthesia, the pig was placed in the supine position. A vertical incision of about 10 cm was made in the right side of the neck to expose about 3 cm of the right external jugular vein and the right internal carotid artery (CA). The peripheral side of the right internal CA was ligated with a 1--0 silk thread, a bulldog clip was applied to the medial side, and after An incision was made in CA, a catheter was advanced through the artery to about 5 cm and secured. Subsequently, another prepared catheter was inserted through the right external jugular vein and advanced approximately 25 cm toward the upper hepatic inferior vena cava and fixed. After confirming sufficient reflux blood could be obtained from both catheters, the skin incision was continuously sutured with 5--0 nylon thread.

Next, a midline incision of the upper abdomen was made about 30 cm below the xiphoid process, and the abdomen was opened. The intestinal tract was held to the left to expose the hepatic portal region. An incision was made in the pancreatic vein and a catheter was inserted about 3 cm toward the hepatic portal. The midline incision was closed by continuous suture with 5--0 nylon thread.

Protocol for achieving a single inhalation of H~2~ {#sec005}
--------------------------------------------------

A median sternum incision was made from the xiphoid process toward the head. At the end of an expiration, the ventilator was removed to stop the animal breathing, and both lungs were manually compressed to mimic maximal forced exhalation by eliminating residual air.

A beach ball was filled with 100% H~2~ using a hydrogen gas filling device from DAYS (Doctorsman Co., Ltd.) containing hydrogen-absorbing alloys \[DAYS (Doctorsman Co., Ltd.)\] \[[@pone.0234626.ref010]\] (**[Fig 1](#pone.0234626.g001){ref-type="fig"}**). The device contained a coupler consisting of a plug and socket with a built-in valve, so when the plug and socket were separated, the inflow of air into the beach ball was completely blocked. The beach ball was connected to a tracheal tube then squeezed, using both hands, at a pressure of about 20 mmHg, to fill the lungs with 100% H~2~. This reflected the manner in which a bag valve mask would be pressed. The H~2~-filled lungs were kept at maximal inspiration for approximately 30 s before the tracheal tube was connected to the ventilator and breathing was resumed.

![Beach ball being filled with 100% H~2~.\
The ball is expanding with H~2~ released from a hydrogen-absorbing alloy in an H~2~ filling device.](pone.0234626.g001){#pone.0234626.g001}

Blood sampling for H~2~ concentration measurement {#sec006}
-------------------------------------------------

Blood was collected from the three intravascular catheters. First, blood was collected in the steady-state condition (before the breath hold, with the chest open). Next, two sets of experiments were performed per pig. In the first set, blood was collected immediately after the breath hold and at 3, 10, 30, and 60 min after restarting ventilation. In the second set, blood was collected immediately after the breath hold and at 3 and 10 min after restarting ventilation.

Measurement of H~2~ concentration {#sec007}
---------------------------------

A needle was inserted into the rubber lid of a 13.5-mL sealed vial, 1 mL of air was extracted, and 1 mL of blood was injected. To prevent outgassing, wax was immediately applied to the rubber lid and the injected hole was sealed.

H~2~ in the blood was released into the air phase in the closed vial. Some of the air phase (0.2 mL, 0.4 mL or 1 mL, depending on the H~2~ concentration) was collected from the vial and H~2~ concentration was measured by gas chromatography (TRIlyzer mBA-3000, Taiyo, Co., Ltd. Osaka, Japan). A calibration curve was obtained using standard H~2~ gas of 0, 5, 50 and 130 ppm. Each sample was measured twice. The concentration of the sample taken before H~2~ inhalation was subtracted as background.

Statistical analysis {#sec008}
--------------------

Data are expressed as the mean ± standard error of the mean. One-way analysis of variance followed by a Tukey--Kramer multiple comparisons test was used to compare the H~2~ concentrations between measurement sites. *P* \< 0.05 was considered significant. All data were analyzed using GraphPad Prism 8.4 (GraphPad Software Inc., La Jolla, CA).

Results {#sec009}
=======

H~2~ concentration in circulating blood at steady state {#sec010}
-------------------------------------------------------

Mammalian cells do not produce H~2~ as they lack the hydrogenase activity necessary for its formation. Instead, resident bacteria in the colon produce a considerable amount of H~2~ via anaerobic fermentation of unabsorbed carbohydrates. It is generally assumed that H~2~ produced by bacterial fermentation in the colon is transferred to the portal circulation and excreted through the breath. In a previous breath gas analysis we conducted in healthy volunteers, we found that the concentration of H~2~ in the breath varies widely (1--56 ppm) between individuals \[[@pone.0234626.ref011]\].

In the present experiment, we detected minimal H~2~ in the carotid artery (CA) in the steady-state condition in both pigs. In contrast, H~2~ concentration in the portal vein (PV) was 67 nL/mL and 8.8 nL/mL for the first and second pigs, respectively, and in the supra-hepatic inferior vena cava (IVC) it was 18 nL/mL and 1.9 nL/mL, respectively. We expect that the large difference between the two pigs in PV H~2~ concentration is due to differences in H~2~ production ability by colonic bacteria.

These results indicate that H~2~ produced by bacteria in the colon is carried by the portal circulation, most of it is trapped in the liver, and the remaining H~2~ is excreted from the lungs.

Pharmacokinetics a single inhalation of H~2~ {#sec011}
--------------------------------------------

In the first set of experiments, blood H~2~ concentration was tracked until 60 min after breathing was resumed. After that, breathing was stopped again at the end of an exhalation and the lungs were manually compressed to reduce residual air, and then expanded with 100% H~2~ for the second set of experiments. In the second set, H~2~ concentration in the circulating blood was monitored for 10 min.

Immediately after the end of the breath hold, the peak H~2~ concentration in the CA of the first pig was 5000 nL/mL in the first set of experiments and 7900 nL/mL in the second set. In the second pig, the concentrations were 10000 and 11000 nL/mL, respectively. (**[Fig 2A](#pone.0234626.g002){ref-type="fig"}**). H~2~ concentration of a 100% aqueous solution was 17,600 nL/mL, meaning that peak H~2~ in the CA reached 28--60% saturation by this inhalation method. Peak H~2~ concentration in venous blood (PV, IVC) was much lower than that in arterial blood (CA\>\>PV\>IVC). This indicates that H~2~ is not simply diffused, but diffuses while being carried by the bloodstream (advection diffusion), and most H~2~ is consumed by the tissues.

![Time course of blood concentration of H~2~ after a single inhalation.\
(A) Peak H~2~ concentration in the CA reached 28--60% saturation. Peak H~2~ concentration in venous blood (PV, IVC) was much lower than that in arterial blood (CA\>\>PV\>IVC). (B) Enlarged low-concentration areas from [Fig 3A](#pone.0234626.g003){ref-type="fig"}. After 10 min, blood H~2~ concentrations were highest in the IVC, then the PV, and lowest in the CA. After 60 min, H~2~ concentration in the PV and IVC remained higher than at steady state. In A and B, upper and lower graphs in each panel show readings from pig 1 and pig 2, respectively. Duplicate H~2~ concentration measurements are overlaid. CA, carotid artery; PV, portal vein; IVC, supra-hepatic inferior vena cava.](pone.0234626.g002){#pone.0234626.g002}

H~2~ concentration decreases rapidly in arterial blood (half-life: 92 s) but more slowly in venous blood (half-life: PV, 310 s; IVC, 350 s) (**[Fig 2B](#pone.0234626.g002){ref-type="fig"}**). Consequently, H~2~ concentration after 10 min was greatest in the IVC, then in the PV, and lowest in the CA (**[Fig 3](#pone.0234626.g003){ref-type="fig"}**)---the opposite to that at peak concentration. At 60 min after resuming breathing, H~2~ in the CA had almost disappeared (2.5 nL/mL) (**[Fig 4](#pone.0234626.g004){ref-type="fig"}**), but higher concentrations of H~2~ were detected in the PV and IVC than at steady state. These results indicate that H~2~ is absorbed in the tissues, then gradually exits the tissues and returns to the heart via venous flow. In other words, a considerable amount of H~2~ remains in the tissues throughout the body even 60 min after inhalation of H~2~.

![Blood concentration of H~2~ 10 min after a single inhalation.\
Venous H~2~ concentrations (PV, IVC) were significantly higher than arterial H~2~ concentrations (CA). Individual readings (two readings from two animals from each intravascular catheter) and means are shown.](pone.0234626.g003){#pone.0234626.g003}

![Blood concentration of H~2~ 60 min after a single inhalation.\
By 60 min, H~2~ had almost disappeared in the CA but remained in the IVC and PV. Data are one reading per animal from each intravascular catheter.](pone.0234626.g004){#pone.0234626.g004}

Discussion {#sec012}
==========

This is the first preclinical study to investigate the kinetics of single-dose inhalation of H~2~ in the body. We devised a protocol that allows pigs to inhale H~2~ only once. The ventilator was removed from the intubated pig at the end of expiration. Both lungs were compressed by hand to release the remaining air. We defined this state as the estimated position at maximum exhalation. A beach ball filled with 100% H~2~ was connected to a tracheal tube and H~2~ was pumped into the lungs until inflated to the estimated position of maximal inspiration by squeezing the beach ball with both arms. We kept the H~2~-inflated lungs intact for a while. We modeled the behavior of holding the breath after inhaling as much H~2~ as possible using this series of methods.

Since many animal experiments \[[@pone.0234626.ref012]--[@pone.0234626.ref014]\] and clinical studies \[[@pone.0234626.ref004], [@pone.0234626.ref005], [@pone.0234626.ref015]\] have been conducted to examine the protective effect of H~2~ inhalation on the brain, the CA was chosen as the first blood collection point to prove that the inhaled H~2~ can reach the brain efficiently. The liver has a dual blood supply from the PV and the hepatic artery. About 75% of the blood flow to the liver comes from the PV and 25% from the hepatic artery. Oxygen is supplied by the PV and the hepatic artery in half each. Therefore, in contrast to the brain, the liver has been regarded as the organ where inhaled H~2~ is least likely to reach \[[@pone.0234626.ref016]\]. The liver is the largest organ in the body, performing a number of functions that are essential for life, such as metabolism, detoxification, and excretion, so protecting it with H~2~ is considered to be a great advantage. We wanted to find out how much H~2~ is consumed as it passes through the liver, so we compared the H~2~ concentrations in the PV and supra-hepatic IVC. The H~2~ concentration of CA immediately after inhalation was very high, and it was confirmed that the inhaled H~2~ reached the brain efficiently. The peak H~2~ concentrations of PV and IVC were 40% and 14% of CA, respectively, indicating that inhaled H~2~ is relatively difficult to reach the liver, but the liver actively consumes the H~2~.

H~2~ circulates throughout the body, with only about 10% returning to the venous blood. The arterial blood H~2~ concentration drops rapidly and has a half-life of about 90 seconds. On the other hand, the half-life of venous blood H~2~ concentrations is longer, 310 seconds for PV and 350 seconds for IVC; therefore, 3 minutes after inhalation, H~2~ concentrations in venous blood exceed those in arterial blood. This is presumed to be due to the fact that the H~2~ diffused into the tissues, which was not metabolized, is gradually returned to the venous blood. H~2~ can still be detected in venous blood an hour after a single inhalation, but H~2~ is almost undetectable in arterial blood, perhaps because it is discarded from the lungs.

Gaseous molecules, such as oxygen, carbon dioxide, nitric oxide, and hydrogen sulfide, can bind to the ferrous heme of a variety of proteins with high affinity; thus, they bind to hemoglobin. H~2~, however, does not bind to heme, and its receptor molecules and their downstream effectors have not yet been identified. Inhaled H~2~ is simply dissolved in the plasma and transported to the whole body. Supply of H~2~ via the arterial blood to the tissues depends on blood flow. However, unlike for oxygen, there is no system that keeps H~2~ concentrated in the blood vessels, so it diffuses out of the blood vessels as it travels.

Whether H~2~ is inhaled or drunk in water enriched with dissolved H~2~ \[[@pone.0234626.ref017], [@pone.0234626.ref018]\], breath analysis shows that 60% is excreted in the breath, with 40% being consumed by the body. The amount of H~2~ released from the body surface is estimated to be extremely small---about 0.1% \[[@pone.0234626.ref017]\]. By comparing the H~2~ concentration in the PV and IVC, we estimate that 64% of H~2~ in the portal blood is trapped just by passing through the liver. Together, these results indicate that H~2~ is consumed by the body, but the molecular mechanism of how H~2~ is metabolized remains unknown.

We, at the Center for Molecular Hydrogen Medicine at Keio University in Tokyo, have demonstrated the therapeutic effects of H~2~ on diseases such as acute myocardial infarction \[[@pone.0234626.ref003], [@pone.0234626.ref007]\], post-cardiac arrest syndrome \[[@pone.0234626.ref004], [@pone.0234626.ref005], [@pone.0234626.ref013], [@pone.0234626.ref014]\], hemorrhagic shock \[[@pone.0234626.ref019], [@pone.0234626.ref020]\], and organ transplantation \[[@pone.0234626.ref010]\] in both animal experiments and clinical studies. In patients with severe COVID-19, the immune over-response causes the production of large amounts of cytokines by alveolar macrophages, which becomes a cytokine storm, resulting in the progression of acute respiratory distress syndrome, abnormal blood coagulation, and multiple organ failure \[[@pone.0234626.ref021]\]. H~2~ gas not only inhibits the overproduction of cytokines \[[@pone.0234626.ref013]\], but also suppresses vascular endothelial damage \[[@pone.0234626.ref020]\], facilitates the flow of red blood cells in microvessels and increases the efficiency of gas exchange (M.S. unpublished observation). Accordingly, H~2~ inhalation therapy has great potential to improve the life expectancy of intubated COVID-19 patients admitted to the intensive care unit with severe hypoxemia. The HYBRID II Trial (Efficacy of inhaled HYdrogen on neurological outcome following BRain Ischemia During out-of-hospital cardiac arrest), a multicenter, randomized, double-blind, placebo-controlled, controlled clinical trial investigating the efficacy of H~2~ inhalation therapy for patients after out-of-hospital cardiac arrest, has been underway since 2017 using a hydrogenated oxygen supply device jointly developed by Keio University and Taiyo Nippon Sanso (jRCTs031180352) \[[@pone.0234626.ref004]\]. In the HYBRID II trial, patients after cardiopulmonary arrest and resuscitation have been treated with hydrogenated oxygen for 18 hours in combination with conventional cooling methods. Prior to Hybrid II, we had conducted an open-label, single-arm, prospective interventional trial at Keio University Hospital in Tokyo in 2014 to evaluate the feasibility and safety of H~2~ inhalation in patients with out-of-hospital cardiac arrest achieved a spontaneous return of circulation \[[@pone.0234626.ref005]\]. Non-cardiogenic cardiac arrest patients were also enrolled in this TRIAL; 5 patients were entered, one of whom was a CA patient due to severe pneumonia and septic shock. This patient had a stable respiratory state during H~2~ inhalation, but died after H~2~ inhalation was completed due to a rapid deterioration of the respiratory state. Based on this experience, we are considering a study protocol in which patients with severe COVID-19 disease will continue to receive hydrogenated oxygen for at least one week until their hypoxemia has sufficiently improved. In China, the hydrogen-oxygen mixture gas inhaler was certified as a national class III medical device in February, and it is reported to have a certain effect on the improvement of hypoxic symptoms of COVID-19-related pneumonia. We hope to bring this new treatment to patients as quickly as possible in order to save the lives of severely ill patients with COVID-19.

Conclusion {#sec013}
==========

We developed a pig model in which we could study the pharmacokinetics of a single inhalation of H~2~. Inhaled H~2~ was transported to the whole body by advection diffusion, and metabolized dynamically. The present results will contribute to the knowledge on H~2~ biology that is increasingly being applied to medicine.

The authors are grateful to Yasuyo Aoyama (Doctors Man Co., Ltd.), Keiji Kawagoe (Toku Corporation), Suga Kato (JHyPA) and Mayumi Takeda (JHyPA) for technical assistance.

10.1371/journal.pone.0234626.r001

Decision Letter 0

Minamino

Tohru

Academic Editor

© 2020 Tohru Minamino

2020

Tohru Minamino

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

5 May 2020

PONE-D-20-11712

Pharmacokinetics of a single inhalation of hydrogen gas in pigs

PLOS ONE

Dear Dr. Sano,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Jun 19 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Tohru Minamino, M.D., Ph.D.

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements:

1.    Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. We note that you have stated that Animals were handled in accordance with the Animal (Scientific Procedures) Act 1986 of the United Kingdom. However, the study appears to have been conducted in Japan. Please confirm that you abided by all local regulations relating the use of animals in scientific procedures.

3\. Thank you for stating the following in the Competing Interests section:

\"S.O. is a founder and CEO of Mitos, Co., Ltd, and the holder of a patent for the use of H2. M.S. and E.K. receive advisory fees from Doctors Man Co., Ltd. M.S. receives advisory fees and research fees from Taiyo Nippon Sanso.\"

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors [http://journals.plos.org/plosone/s/competing-interests](about:blank)).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: [http://journals.plos.org/plosone/s/competing-interests](about:blank)

4\. We note that you have a patent relating to material pertinent to this article. Please provide an amended statement of Competing Interests to declare this patent (with details including name and number), along with any other relevant declarations relating to employment, consultancy, patents, products in development or modified products etc. Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, as detailed online in our guide for authors [http://journals.plos.org/plosone/s/competing-interests](about:blank) by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

This information should be included in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: [http://journals.plos.org/plosone/s/competing-interests](about:blank)

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: No

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This study is a non-clinical pharmacokinetic study of hydrogen in pigs. In addition to the reduction of ischemia-reperfusion injury in the emergency room, hydrogen is also expected to be effective in the treatment of pneumonia with COVID-19, which is currently undergoing clinical trials.　Non-clinical pharmacokinetic studies are required to obtain regulatory approval, but no credible experimental results have been reported to date. This study investigates in detail how hydrogen absorbed from the lungs is transported into the body and metabolized. It is a very well-prepared experiment. It is also valuable in terms of non-clinical pharmacokinetic studies in pigs. I\'ll only mention minor comments.

Comments

1). As COVID-19 spread across the globe, scientists are hunting for drugs that could be repurposed as a quick way to tackle the disease. Hydrogen is one such candidate. Therefore, please describe in the discussion the possible mechanisms by which hydrogen may be effective in the treatment of COVID-19-related pneumonia.

2). Why were blood concentrations monitored at three locations: the carotid artery and portal vein and the supra-hepatic inferior vena cava?

Reviewer \#2: To the editor

As a versatile medical gas candidate, hydrogen has attracted much attention in Asia, especially in Japan, China, and Korea, and has been subjected to animal experiments and clinical trials. To date, the only studies to examine the distribution of hydrogen in the body after the hydrogen intake have been conducted in rats, which are small animals. It is significant to investigate the pharmacokinetics of hydrogen in pigs, which are large animals with anatomical similarities to humans. The accuracy of the experiment is high and the results are credible. I would like to offer some minor comments.

To the authors

This study examined how hydrogen absorbed from the lungs diffuses throughout the body when pigs are given a single dose of hydrogen inhalation. After collapsing the lungs by opening the chest, the remaining air in the lungs is expelled by hand compression, and then the lungs are inflated with hydrogen to the level of the maximum inspiratory volume. By maintaining this state for a while, the authors create a state in which the maximum possible dose of hydrogen is taken up from the lungs into the blood. Blood samples are drawn from the carotid artery, portal vein, and supra-hepatic IVC to monitor the kinetics of hydrogen concentrations in the blood. The authors conclude that hydrogen gas is transported to each organ in a blood flow-dependent manner, where it is actively metabolized. As a versatile medical gas candidate, hydrogen has attracted much attention in Asia, especially in Japan, China, and Korea, and has been subjected to animal experiments and clinical trials. To date, the only studies to examine the distribution of hydrogen in the body after the hydrogen intake have been conducted in rats, which are small animals. It is significant to investigate the pharmacokinetics of hydrogen in pigs, which are large animals with anatomical similarities to humans. The accuracy of the experiment is high and the results are credible. I would like to offer some minor comments.

Comments

\(1\) This paper examines the pharmacokinetics after hydrogen inhalation, but for the general reader, it should touch on the known pharmacology of hydrogen, such as its antioxidant and anti-inflammatory effects.

\(2\) Hydrogen can be taken into the body not only by inhalation, but also by drinking hydrogen-containing water. What is the pharmacokinetics of hydrogen dissolved in orally ingested water, in analogy with the present experimental results?

Reviewer \#3: In this study, the concentration of hydrogen in the blood was measured at three locations: the carotid artery, the portal vein, and the supra-hepatic inferior inferior vena cava, after a single inhalation of hydrogen gas in pigs. Although many preclinical and clinical trials have shown the therapeutic effect of hydrogen on a variety of conditions involving ischemia-reperfusion injury, information on how ingested hydrogen is distributed throughout the body is scarce. It is significant that the present study proved that hydrogen absorbed from the lungs is transported by advection diffusion in the bloodstream to systemic organs, rather than by simple diffusion. This study is presented by a group that is leading the world in non-clinical and clinical research on hydrogen gas. The surgery is performed by a transplant surgeon with extensive experience in pig surgery. The concentration of hydrogen was measured by gas chromatography with little error between the two measurements, and the accuracy of the data is high. This data is necessary for hydrogen to be approved by the pharmaceutical industry as a medical gas in the future. I\'ll only mention minor comments.

Comment:

\(1\) Why did you insist on single-dose inhalation instead of continuous inhalation?

\(2\) The treatment of pneumonia caused by COVID-19 has started in Wuhan, China. Please describe the expected pharmacological effects of hydrogen in this clinical setting.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Comments to the Author

Reviewer \#1:

This study is a non-clinical pharmacokinetic study of hydrogen in pigs. In addition to the reduction of ischemia-reperfusion injury in the emergency room, hydrogen is also expected to be effective in the treatment of pneumonia with COVID-19, which is currently undergoing clinical trials.　Non-clinical pharmacokinetic studies are required to obtain regulatory approval, but no credible experimental results have been reported to date. This study investigates in detail how hydrogen absorbed from the lungs is transported into the body and metabolized. It is a very well-prepared experiment. It is also valuable in terms of non-clinical pharmacokinetic studies in pigs. I\'ll only mention minor comments.

Comments

1). As COVID-19 spread across the globe, scientists are hunting for drugs that could be repurposed as a quick way to tackle the disease. Hydrogen is one such candidate. Therefore, please describe in the discussion the possible mechanisms by which hydrogen may be effective in the treatment of COVID-19-related pneumonia.

Response

Thank you very much for kind remarks. We, at the Center for Molecular Hydrogen Medicine at Keio University in Tokyo, have demonstrated the therapeutic effects of H2 on diseases such as acute myocardial infarction \[3, 7\], post-cardiac arrest syndrome \[4, 5, 13, 14\], hemorrhagic shock \[19, 20\], and organ transplantation \[10\] in both animal experiments and clinical studies. In patients with severe COVID-19, the immune over-response causes the production of large amounts of cytokines by alveolar macrophages, which becomes a cytokine storm, resulting in the progression of acute respiratory distress syndrome, abnormal blood coagulation, and multiple organ failure \[21\]. H2 gas not only inhibits the overproduction of cytokines \[13\], but also suppresses vascular endothelial damage \[20\], facilitates the flow of red blood cells in microvessels and increases the efficiency of gas exchange (M.S. unpublished observation). Accordingly, H2 inhalation therapy has great potential to improve the life expectancy of intubated COVID-19 patients admitted to the intensive care unit with severe hypoxemia. The HYBRID II Trial (Efficacy of inhaled HYdrogen on neurological outcome following BRain Ischemia During out-of-hospital cardiac arrest), a multicenter, randomized, double-blind, placebo-controlled, controlled clinical trial investigating the efficacy of H2 inhalation therapy for patients after out-of-hospital cardiac arrest, has been underway since 2017 using a hydrogenated oxygen supply device jointly developed by Keio University and Taiyo Nippon Sanso (jRCTs031180352)\[4\]. In the HYBRID II trial, patients after cardiopulmonary arrest and resuscitation have been treated with hydrogenated oxygen for 18 hours in combination with conventional cooling methods. Prior to Hybrid II, we had conducted an open-label, single-arm, prospective interventional trial at Keio University Hospital in Tokyo in 2014 to evaluate the feasibility and safety of H2 inhalation in patients with out-of-hospital cardiac arrest achieved a spontaneous return of circulation \[5\]. Non-cardiogenic cardiac arrest patients were also enrolled in this TRIAL; 5 patients were entered, one of whom was a CA patient due to severe pneumonia and septic shock. This patient had a stable respiratory state during H2 inhalation, but died after H2 inhalation was completed due to a rapid deterioration of the respiratory state. Based on this experience, we are considering a study protocol in which patients with severe COVID-19 disease will continue to receive hydrogenated oxygen for at least one week until their hypoxemia has sufficiently improved. In China, the hydrogen-oxygen mixture gas inhaler was certified as a national class III medical device in February, and it is reported to have a certain effect on the improvement of hypoxic symptoms of COVID-19-related pneumonia. We hope to bring this new treatment to patients as quickly as possible in order to save the lives of severely ill patients with COVID-19.

2). Why were blood concentrations monitored at three locations: the carotid artery and portal vein and the supra-hepatic inferior vena cava?

In the Discussion section, I added the reasons why I measured the hydrogen concentration at the three locations as follows.

As several clinical studies have been reported or are underway to validate the efficacy of hydrogen inhalation for brain damage, the carotid artery was chosen as the first blood collection point to prove that the inhaled hydrogen can reach the brain efficiently.

The liver has a dual blood supply from the portal vein and the hepatic artery. About 75% of the blood flow to the liver comes from the portal vein and 25% from the hepatic artery. Oxygen is supplied by the portal vein and the hepatic artery in half each. Therefore, in contrast to the brain, the liver has been regarded as the organ where inhaled hydrogen is least likely to reach. The liver is the largest organ in the body, performing a number of functions that are essential for life, such as metabolism, detoxification, and excretion, so protecting it with H2 is considered to be a great advantage. Therefore, we wanted to find out how much H2 is consumed as it passes through the liver, so we compared the H2 concentrations in the portal vein and supra-hepatic IVC.

Reviewer \#2:

This study examined how hydrogen absorbed from the lungs diffuses throughout the body when pigs are given a single dose of hydrogen inhalation. After collapsing the lungs by opening the chest, the remaining air in the lungs is expelled by hand compression, and then the lungs are inflated with hydrogen to the level of the maximum inspiratory volume. By maintaining this state for a while, the authors create a state in which the maximum possible dose of hydrogen is taken up from the lungs into the blood. Blood samples are drawn from the carotid artery, portal vein, and supra-hepatic IVC to monitor the kinetics of hydrogen concentrations in the blood. The authors conclude that hydrogen gas is transported to each organ in a blood flow-dependent manner, where it is actively metabolized. As a versatile medical gas candidate, hydrogen has attracted much attention in Asia, especially in Japan, China, and Korea, and has been subjected to animal experiments and clinical trials. To date, the only studies to examine the distribution of hydrogen in the body after the hydrogen intake have been conducted in rats, which are small animals. It is significant to investigate the pharmacokinetics of hydrogen in pigs, which are large animals with anatomical similarities to humans. The accuracy of the experiment is high and the results are credible. I would like to offer some minor comments.

Comments

\(1\) This paper examines the pharmacokinetics after hydrogen inhalation, but for the general reader, it should touch on the known pharmacology of hydrogen, such as its antioxidant and anti-inflammatory effects.

Response

Thank you very much for summarizing the manuscript and for your positive comments.

The biological effects of H2 are explained in relation to the expected therapeutic effects of H2 on COVID-19 in the discussion section.

"In patients with severe COVID-19, the immune over-response causes the production of large amounts of cytokines by alveolar macrophages, which becomes a cytokine storm, resulting in the progression of acute respiratory distress syndrome, abnormal blood coagulation, and multiple organ failure \[21\]. H2 gas not only inhibits the overproduction of cytokines \[13\], but also suppresses vascular endothelial damage \[20\], facilitates the flow of red blood cells in microvessels and increases the efficiency of gas exchange (M.S. unpublished observation). Accordingly, H2 inhalation therapy has great potential to improve the life expectancy of intubated COVID-19 patients admitted to the intensive care unit with severe hypoxemia. The HYBRID II Trial (Efficacy of inhaled HYdrogen on neurological outcome following BRain Ischemia During out-of-hospital cardiac arrest), a multicenter, randomized, double-blind, placebo-controlled, controlled clinical trial investigating the efficacy of H2 inhalation therapy for patients after out-of-hospital cardiac arrest, has been underway since 2017 using a hydrogenated oxygen supply device jointly developed by Keio University and Taiyo Nippon Sanso (jRCTs031180352)\[4\]. In the HYBRID II trial, patients after cardiopulmonary arrest and resuscitation have been treated with hydrogenated oxygen for 18 hours in combination with conventional cooling methods. Prior to Hybrid II, we had conducted an open-label, single-arm, prospective interventional trial at Keio University Hospital in Tokyo in 2014 to evaluate the feasibility and safety of H2 inhalation in patients with out-of-hospital cardiac arrest achieved a spontaneous return of circulation \[5\]. Non-cardiogenic cardiac arrest patients were also enrolled in this TRIAL; 5 patients were entered, one of whom was a CA patient due to severe pneumonia and septic shock. This patient had a stable respiratory state during H2 inhalation, but died after H2 inhalation was completed due to a rapid deterioration of the respiratory state. Based on this experience, we are considering a study protocol in which patients with severe COVID-19 disease will continue to receive hydrogenated oxygen for at least one week until their hypoxemia has sufficiently improved".

\(2\) Hydrogen can be taken into the body not only by inhalation, but also by drinking hydrogen-containing water. What is the pharmacokinetics of hydrogen dissolved in orally ingested water, in analogy with the present experimental results?

Response

If someone drinks H2-rich water, it will be absorbed from the gastrointestinal tract and will first pass through the liver. Our experimental results suggest that most H2 is actively consumed by the liver. Some H2 passes through the liver, but most of it will be discarded in the atmosphere while passing through the lungs. Certainly, the concentration of H2 in the exhaled air after drinking the H2-rich water increases. How much H2 reaches the left ventricle and is supplied to the whole body can be determined by feeding pigs high H2 water and then measuring the H2 concentration in a similar manner.

Reviewer \#3: In this study, the concentration of hydrogen in the blood was measured at three locations: the carotid artery, the portal vein, and the supra-hepatic inferior inferior vena cava, after a single inhalation of hydrogen gas in pigs. Although many preclinical and clinical trials have shown the therapeutic effect of hydrogen on a variety of conditions involving ischemia-reperfusion injury, information on how ingested hydrogen is distributed throughout the body is scarce. It is significant that the present study proved that hydrogen absorbed from the lungs is transported by advection diffusion in the bloodstream to systemic organs, rather than by simple diffusion. This study is presented by a group that is leading the world in non-clinical and clinical research on hydrogen gas. The surgery is performed by a transplant surgeon with extensive experience in pig surgery. The concentration of hydrogen was measured by gas chromatography with little error between the two measurements, and the accuracy of the data is high. This data is necessary for hydrogen to be approved by the pharmaceutical industry as a medical gas in the future. I\'ll only mention minor comments.

Comment:

\(1\) Why did you insist on single-dose inhalation instead of continuous inhalation?

Response

Thank you very much for summarizing the manuscript and for your positive comments. An explanation of why a single inhalation test was performed has been added to the introduction section.

"In a non-clinical pharmacokinetic study, the distribution of a test drug to various organs and tissues after a single or repeated dose and its change over time should be investigated. In the case of gas, unlike oral and injectable drugs, a non-clinical pharmacokinetic study with a single dose has not been performed. This was because there was no animal protocol for a single-dose study of the gas. The same is true for H2. The distribution of H2 to various organs and tissues after sustained inhalation has been studied in small animals such as rats. However, it was not possible to determine from these experiments whether H2 diffused from the lungs in a blood flow-independent manner or whether H2 was transported throughout the body in a blood flow-dependent manner. Therefore, in the present study, we devised an animal protocol for single-dose inhalation of gas and proved the latter to be true for the first time".

\(2\) The treatment of pneumonia caused by COVID-19 has started in Wuhan, China. Please describe the expected pharmacological effects of hydrogen in this clinical setting.

The expected pharmacological effects of hydrogen in this clinical setting were described in the discussion section as follows.

"In patients with severe COVID-19, the immune over-response causes the production of large amounts of cytokines by alveolar macrophages, which becomes a cytokine storm, resulting in the progression of acute respiratory distress syndrome, abnormal blood coagulation, and multiple organ failure \[21\]. H2 gas not only inhibits the overproduction of cytokines \[13\], but also suppresses vascular endothelial damage \[20\], facilitates the flow of red blood cells in microvessels and increases the efficiency of gas exchange (M.S. unpublished observation). Accordingly, H2 inhalation therapy has great potential to improve the life expectancy of intubated COVID-19 patients admitted to the intensive care unit with severe hypoxemia. The HYBRID II Trial (Efficacy of inhaled HYdrogen on neurological outcome following BRain Ischemia During out-of-hospital cardiac arrest), a multicenter, randomized, double-blind, placebo-controlled, controlled clinical trial investigating the efficacy of H2 inhalation therapy for patients after out-of-hospital cardiac arrest, has been underway since 2017 using a hydrogenated oxygen supply device jointly developed by Keio University and Taiyo Nippon Sanso (jRCTs031180352)\[4\]. In the HYBRID II trial, patients after cardiopulmonary arrest and resuscitation have been treated with hydrogenated oxygen for 18 hours in combination with conventional cooling methods. Prior to Hybrid II, we had conducted an open-label, single-arm, prospective interventional trial at Keio University Hospital in Tokyo in 2014 to evaluate the feasibility and safety of H2 inhalation in patients with out-of-hospital cardiac arrest achieved a spontaneous return of circulation \[5\]. Non-cardiogenic cardiac arrest patients were also enrolled in this TRIAL; 5 patients were entered, one of whom was a CA patient due to severe pneumonia and septic shock. This patient had a stable respiratory state during H2 inhalation, but died after H2 inhalation was completed due to a rapid deterioration of the respiratory state. Based on this experience, we are considering a study protocol in which patients with severe COVID-19 disease will continue to receive hydrogenated oxygen for at least one week until their hypoxemia has sufficiently improved".

10.1371/journal.pone.0234626.r003
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